# Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote

> **NCT07032142** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **D'Or Institute for Research and Education** · enrollment: 66 (estimated)

## Conditions studied

- Cancer
- Toxicity Due to Chemotherapy

## Interventions

- **DRUG:** I-01/23

## Key facts

- **NCT ID:** NCT07032142
- **Lead sponsor:** D'Or Institute for Research and Education
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07
- **Primary completion:** 2028-07
- **Final completion:** 2028-07
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07032142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07032142, "Dose Optimization and Efficacy Assessment of a Fluoropyrimidine Antidote". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07032142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*